| An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ... (NCT00924092) | National Cancer Institute (NCI) | 2009-03-13 |
| Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor (NCT00923390) | National Cancer Institute (NCI) | 2009-03-02 |
| Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer (NCT00860886) | National Cancer Institute (NCI) | 2009-03-02 |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma (NCT00866177) | National Cancer Institute (NCI) | 2009-03-01 |
| Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT00873093) | National Cancer Institute (NCI) | 2009-03-01 |
| A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer (NCT00924209) | National Cancer Institute (NCI) | 2009-03-01 |
| Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System (NCT00867178) | National Cancer Institute (NCI) | 2009-02-25 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (NCT00770809) | National Cancer Institute (NCI) | 2009-02-24 |
| A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) (NCT00923247) | National Cancer Institute (NCI) | 2009-02-19 |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma (NCT00924326) | National Cancer Institute (NCI) | 2009-02-17 |
| The Natural History of Solid Organ Cancer Stem Cells (SOCSC) (NCT00923052) | National Cancer Institute (NCI) | 2009-02-09 |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia (NCT00924040) | National Cancer Institute (NCI) | 2009-02-01 |
| Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma (NCT00841204) | National Cancer Institute (NCI) | 2009-02-01 |
| Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery (NCT00848016) | National Cancer Institute (NCI) | 2009-02-01 |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (NCT00843882) | National Cancer Institute (NCI) | 2009-01-29 |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (NCT01445535) | National Cancer Institute (NCI) | 2009-01-13 |
| Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer (NCT00923130) | National Cancer Institute (NCI) | 2009-01-07 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (NCT00831844) | National Cancer Institute (NCI) | 2009-01-01 |
| Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma (NCT00521092) | National Cancer Institute (NCI) | 2009-01-01 |
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment (NCT00822458) | National Cancer Institute (NCI) | 2009-01-01 |
| Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors (NCT01445509) | National Cancer Institute (NCI) | 2008-12-29 |
| Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease (NCT00702689) | National Cancer Institute (NCI) | 2008-12-15 |
| Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (NCT00769379) | National Cancer Institute (NCI) | 2008-12-10 |
| Blood and Tissue Study of Patients in NIH Protocol 08-C-0800 (NCT00923325) | National Cancer Institute (NCI) | 2008-12-09 |
| Informed Consent in Pediatric Cancer Trials (NCT00923650) | National Cancer Institute (NCI) | 2008-12-09 |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer (NCT01445522) | National Cancer Institute (NCI) | 2008-12-03 |
| Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00658814) | National Cancer Institute (NCI) | 2008-12-01 |
| Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer (NCT00572728) | National Cancer Institute (NCI) | 2008-12-01 |
| Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer (NCT00923806) | National Cancer Institute (NCI) | 2008-12-01 |
| Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma (NCT00923195) | National Cancer Institute (NCI) | 2008-12-01 |
| Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT00693433) | National Cancer Institute (NCI) | 2008-12-01 |
| IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery (NCT00778817) | National Cancer Institute (NCI) | 2008-12-01 |
| Case-Control Study of Inflammatory Breast Cancer in North Africa (NCT00793390) | National Cancer Institute (NCI) | 2008-11-17 |
| Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin (NCT00971620) | National Cancer Institute (NCI) | 2008-11-17 |
| Community Cancer Centers Pilot Patient Survey (NCT00786656) | National Cancer Institute (NCI) | 2008-11-03 |
| R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer (NCT00773955) | National Cancer Institute (NCI) | 2008-11-01 |
| Ixabepilone to Treat Cervical Cancer (NCT00924066) | National Cancer Institute (NCI) | 2008-11-01 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00795002) | National Cancer Institute (NCI) | 2008-11-01 |
| Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer (NCT00924287) | National Cancer Institute (NCI) | 2008-11-01 |
| Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia (NCT00783705) | National Cancer Institute (NCI) | 2008-11-01 |
| Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia (NCT00924170) | National Cancer Institute (NCI) | 2008-10-31 |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00699491) | National Cancer Institute (NCI) | 2008-10-31 |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia (NCT00923013) | National Cancer Institute (NCI) | 2008-10-20 |
| Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health (NCT00776178) | National Cancer Institute (NCI) | 2008-10-17 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function (NCT00674024) | National Cancer Institute (NCI) | 2008-10-07 |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00634244) | National Cancer Institute (NCI) | 2008-10-01 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer (NCT00738881) | National Cancer Institute (NCI) | 2008-10-01 |
| Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00778167) | National Cancer Institute (NCI) | 2008-10-01 |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer (NCT00735917) | National Cancer Institute (NCI) | 2008-10-01 |
| 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma (NCT00775268) | National Cancer Institute (NCI) | 2008-09-29 |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00601900) | National Cancer Institute (NCI) | 2008-09-24 |
| Pharmacokinetic Studies Participation Survey (NCT00923468) | National Cancer Institute (NCI) | 2008-09-23 |
| Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary (NCT00748657) | National Cancer Institute (NCI) | 2008-09-22 |
| Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer (NCT00924313) | National Cancer Institute (NCI) | 2008-09-10 |
| Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00723255) | National Cancer Institute (NCI) | 2008-09-01 |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer (NCT00602043) | National Cancer Institute (NCI) | 2008-09-01 |
| Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00742625) | National Cancer Institute (NCI) | 2008-09-01 |
| Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer (NCT00729586) | National Cancer Institute (NCI) | 2008-09-01 |
| Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805) | National Cancer Institute (NCI) | 2008-08-18 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT00588770) | National Cancer Institute (NCI) | 2008-08-08 |
| Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer (NCT00923949) | National Cancer Institute (NCI) | 2008-08-01 |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer (NCT00471536) | National Cancer Institute (NCI) | 2008-08-01 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (NCT00729157) | National Cancer Institute (NCI) | 2008-08-01 |
| Study of 9cUAB30 in Healthy Participants (NCT00896974) | National Cancer Institute (NCI) | 2008-08-01 |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00735930) | National Cancer Institute (NCI) | 2008-08-01 |
| Resveratrol in Healthy Adult Participants (NCT00721877) | National Cancer Institute (NCI) | 2008-08-01 |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer (NCT00684983) | National Cancer Institute (NCI) | 2008-07-30 |
| Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (NCT00644228) | National Cancer Institute (NCI) | 2008-07-28 |
| Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (NCT00720109) | National Cancer Institute (NCI) | 2008-07-14 |
| Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma (NCT00703664) | National Cancer Institute (NCI) | 2008-07-09 |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas (NCT00727233) | National Cancer Institute (NCI) | 2008-07-08 |
| Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer (NCT00666562) | National Cancer Institute (NCI) | 2008-07-02 |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00719901) | National Cancer Institute (NCI) | 2008-07-01 |
| Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma (NCT00754494) | National Cancer Institute (NCI) | 2008-07-01 |
| Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes (NCT00971789) | National Cancer Institute (NCI) | 2008-07-01 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma (NCT00650923) | National Cancer Institute (NCI) | 2008-07-01 |
| Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme (NCT00641706) | National Cancer Institute (NCI) | 2008-07-01 |
| Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NCT00923741) | National Cancer Institute (NCI) | 2008-06-19 |
| T-Cell Project: Epidemiologic Component (NCT00705809) | National Cancer Institute (NCI) | 2008-06-18 |
| Montelukast to Treat Bronchiolitis Obliterans (NCT00656058) | National Cancer Institute (NCI) | 2008-06-17 |
| Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy (NCT00693992) | National Cancer Institute (NCI) | 2008-06-15 |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients (NCT00706992) | National Cancer Institute (NCI) | 2008-06-01 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (NCT00720174) | National Cancer Institute (NCI) | 2008-06-01 |
| Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer (NCT00684996) | National Cancer Institute (NCI) | 2008-06-01 |
| Sunitinib to Treat Recurrent Brain Cancer (NCT00923117) | National Cancer Institute (NCI) | 2008-06-01 |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia (NCT00703300) | National Cancer Institute (NCI) | 2008-06-01 |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy (NCT00679354) | National Cancer Institute (NCI) | 2008-06-01 |
| Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer (NCT00718809) | National Cancer Institute (NCI) | 2008-06-01 |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer (NCT00670748) | National Cancer Institute (NCI) | 2008-05-29 |
| Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour Recall (NCT01164254) | National Cancer Institute (NCI) | 2008-05-28 |
| AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer (NCT01445418) | National Cancer Institute (NCI) | 2008-05-12 |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00475150) | National Cancer Institute (NCI) | 2008-05-01 |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer (NCT00678769) | National Cancer Institute (NCI) | 2008-05-01 |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers (NCT00678132) | National Cancer Institute (NCI) | 2008-04-24 |
| Follow-Up Study of Kidney Cancer Patients (NCT00656955) | National Cancer Institute (NCI) | 2008-04-17 |
| Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (NCT00698815) | National Cancer Institute (NCI) | 2008-04-15 |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (NCT00667394) | National Cancer Institute (NCI) | 2008-04-01 |